Abstract Number: 857 • 2014 ACR/ARHP Annual Meeting
Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Background/Purpose: BAFF, a potent B cell survival factor, is an established therapeutic target in SLE, with the anti-BAFF antibody, belimumab, being FDA-approved for the treatment…